Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce b...

Full description

Bibliographic Details
Main Author: Melo, Miguel (author)
Other Authors: Gavina, Cristina (author), Silva-Nunes, José (author), Andrade, Luís (author), Carvalho, Davide (author)
Format: article
Language:eng
Published: 2021
Subjects:
Antidiabetic drug
GLP-1 RA
Cardiovascular disease
Cardiovascular outcome trials
Type 2 diabetes
Online Access:http://hdl.handle.net/10316/103850
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/103850

Internet

http://hdl.handle.net/10316/103850

Similar Items